Abstract: An implant for releasing an active substance into a vessel through which a body medium flows. The implant release an active substance into a vessel through which a body medium flows downstream from the location of the implant. A base of a biodegradable material is a carrier of the active substance to be released. The body medium flows past the implant and the active substance is release. The implant is configured so that the active substance does not contact a vessel wall at the location of implant.

Abstract: The invention relates to intraluminal endoprosthesis, preferably a stent consisting essentially of a base body and optionally a coating covering the surface of the base body at least partially. The invention is characterized in that the base body and/or the coating has at least one compound from the group of polyphosphates, magnesium oxyhalides, preferably Sorel cement. Furthermore, a method is described for manufacturing such an intraluminal endoprosthesis.

Abstract: The aim of the invention is to provide an implant for releasing an active substance into a vessel through which a body medium flows. This aim is achieved by the inventive implant for releasing an active substance into a vessel through which a body medium flows. Said implant comprises a base that consists of a biodegradable material as the carrier of the active substance to be released. The body medium flows around said base on the inside and/or outside thereof.

Abstract: The invention concerns an endovascular implant, in particular a stent, with an at least portion-wise active coating. The object of the present invention is to provide locally therapeutic formulations for the treatment of stenosis or restenosis. The implants modified in accordance with the invention are to ensure improved compatibility, in particular in regard to any inflammatory and proliferative processes in the tissue environment. That is achieved in that the active coating includes, as an active substance: 1) PPAR?-agonists, PPAR?-agonists or a combination thereof; 2) an RXR-agonist; or 3) a combination of PPAR-agonists and RXR-agonists.

Abstract: Propolis as a coating material for medical implants. It also relates to the application of propolis, particularly of the constituent caffeic acid phenylethyl ester, for the manufacture of a drug for re-stenosis prophylaxis after percutaneous transluminar coronary angioplasty (PTCA) inhuman coronary arteries.

Abstract: The invention concerns an endovascular implant, in particular a stent, with an at least portion-wise active coating. The object of the present invention is to provide locally therapeutic formulations for the treatment of stenosis or restenosis. The implants modified in accordance with the invention are to ensure improved compatibility, in particular in regard to any inflammatory and proliferative processes in the tissue environment. That is achieved in that the active coating includes, as an active substance: 1) PPAR&agr;-agonists, PPAR&dgr;-agonists or a combination thereof; 2) an RXR-agonist; or 3) a combination of PPAR-agonists and RXR-agonists.